antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-492Research ArticleОБЗОРЫREVIEWSИмипенем: 30 лет терапииImipenem: 30-Year Experience in TherapyСидоренкоС. В.SidorenkoS. V.noemail@neicon.ruПартинаИ. В.PartinaI. V.noemail@neicon.ruАгеевецВ. А.AgeevetsV. A.noemail@neicon.ruФГБУ НИИ детских инфекций ФМБА РоссииРоссияResearch Institute of Children's InfectionsRussian Federation201313052020585-65561Copyright © Сидоренко С.В., Партина И.В., Агеевец В.А., 20202020Сидоренко С.В., Партина И.В., Агеевец В.А.Sidorenko S.V., Partina I.V., Ageevets V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/492ReferencesRodloff A.C., Goldstein E.J.C., Torres A. Two decades of imipenem therapy. J of Antim Chem 2006; 58: 916-929.Rodloff A.C., Goldstein E.J.C., Torres A. Two decades of imipenem therapy. J of Antim Chem 2006; 58: 916-929.Birnbaum J., Kahan F.M., Kropp H. et al. Carbapenems, a new class of β-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985; 787: 3-21.Birnbaum J., Kahan F.M., Kropp H. et al. Carbapenems, a new class of β-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 1985; 787: 3-21.Kropp H., Gerckens L., Sundelof J.G. et al. Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev Infect Dis 1985; 7 Suppl 3: S389-410.Kropp H., Gerckens L., Sundelof J.G. et al. Antibacterial activity of imipenem: the first thienamycin antibiotic. Rev Infect Dis 1985; 7 Suppl 3: S389-410.Watanabe M., Iyobe S., Inoue M., Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 147-151.Watanabe M., Iyobe S., Inoue M., Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 147-151.Senda K., Arakawa Y., Nakashima K., Ito H., Ichiyama S., Shimokata K., Kato N., Ohta M. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996; 40:3 49-353.Senda K., Arakawa Y., Nakashima K., Ito H., Ichiyama S., Shimokata K., Kato N., Ohta M. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996; 40:3 49-353.Pournaras S., Maniati M., Petinaki E., Tzouvelekis L.S., Tsakris A., Legakis N.J., Maniatis A.N. Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-β-lactamase gene variants blaVIM-2 and blaVIM-4. Antimicrob Chemother 2003; 51: 1409-1414.Pournaras S., Maniati M., Petinaki E., Tzouvelekis L.S., Tsakris A., Legakis N.J., Maniatis A.N. Hospital outbreak of multiple clones of Pseudomonas aeruginosa carrying the unrelated metallo-β-lactamase gene variants blaVIM-2 and blaVIM-4. Antimicrob Chemother 2003; 51: 1409-1414.Livermore, D.M., Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000; 3: 489-495.Livermore, D.M., Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000; 3: 489-495.Hota S., Hirji Z., Stockton K. et al. Outbreak of multidrug-resistant Pseudomonas aeruginosa colonization and infection secondary to imperfect intensive care unit room design. Inf Control Hosp Epid 2009; 30: 1.Hota S., Hirji Z., Stockton K. et al. Outbreak of multidrug-resistant Pseudomonas aeruginosa colonization and infection secondary to imperfect intensive care unit room design. Inf Control Hosp Epid 2009; 30: 1.Гостев B.B., Сидоренко C.B. SCCmec кассеты, эволюция и генетические линии метициллинорезистентных золотистых стафилококков. Антибиотики и химиотер. 2012; 9-10: 39-46.Гостев B.B., Сидоренко C.B. SCCmec кассеты, эволюция и генетические линии метициллинорезистентных золотистых стафилококков. Антибиотики и химиотер. 2012; 9-10: 39-46.Mouton J.W., Touw D.J., Horrevorts A.M. et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185-201.Mouton J.W., Touw D.J., Horrevorts A.M. et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185-201.Balfour J., Bryson H., Brogden R. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 99-136.Balfour J., Bryson H., Brogden R. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 99-136.Lavan G., Nord C. Adverse effects of monobactams and carbapenems. Drug Safety 1995; 12: 305-13.Lavan G., Nord C. Adverse effects of monobactams and carbapenems. Drug Safety 1995; 12: 305-13.Drusano G.L., Craig W.A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Chemotherapy 1997; 9 Suppl 3: 38-44;Drusano G.L., Craig W.A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Chemotherapy 1997; 9 Suppl 3: 38-44;Яковлев C.B. Имипенем. Оценка роли препарата при антибактериальной терапии тяжёлых госпитальных инфекций. Антибиотики и химиотер. 1999; 5: 33-37.Яковлев C.B. Имипенем. Оценка роли препарата при антибактериальной терапии тяжёлых госпитальных инфекций. Антибиотики и химиотер. 1999; 5: 33-37.Novelli A., Adembri C., Livi P. et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44: 539-549.Novelli A., Adembri C., Livi P. et al. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44: 539-549.Lee L.S., Bertino J.S. Jr. Comparison of imipenem/cilastatin and meropenem attainment of pharmacodynamic target goals at various dosage regimens using a short infusion time (30 minutes). Clin Pharmacol Therapeut 2004; 75: 14.Lee L.S., Bertino J.S. Jr. Comparison of imipenem/cilastatin and meropenem attainment of pharmacodynamic target goals at various dosage regimens using a short infusion time (30 minutes). Clin Pharmacol Therapeut 2004; 75: 14.Kuti J.L., Dandekar P.K., Nightingale C.H. et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43: 1116-23.Kuti J.L., Dandekar P.K., Nightingale C.H. et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43: 1116-23.Dandekar P.K., Maglio D., Sutherland C.A. et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3 hour infusion. Phamacotherapy 2003; 23: 988-991.Dandekar P.K., Maglio D., Sutherland C.A. et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3 hour infusion. Phamacotherapy 2003; 23: 988-991.Lee L.S., Bertino J.S. Jr. Use of a prolonged infusion time (3 hours) in attaining pharmacodynamic target goals of imipenem-cilastatin and meropenem at various dosing regimens. Clin Pharmacol Therapeut 2004; 75: P15.Lee L.S., Bertino J.S. Jr. Use of a prolonged infusion time (3 hours) in attaining pharmacodynamic target goals of imipenem-cilastatin and meropenem at various dosing regimens. Clin Pharmacol Therapeut 2004; 75: P15.Mattoes H., Kuti J.L., Drusano G.L. et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004; 26: 1187-1198.Mattoes H., Kuti J.L., Drusano G.L. et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004; 26: 1187-1198.Benfield P., Chrisp P. Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intraabdominal infections. PharmacoEconomics 1992; 1: 443-459.Benfield P., Chrisp P. Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intraabdominal infections. PharmacoEconomics 1992; 1: 443-459.Balfour J.A., Bryson H.M., Brogden R.N. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 1: 99-136.Balfour J.A., Bryson H.M., Brogden R.N. Imipenem/cilastatin. An update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996; 51: 1: 99-136.Calandra G.B., Wang C., Aziz M. et al. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimib Chemother 1986; 18: Suppl E: 193-202.Calandra G.B., Wang C., Aziz M. et al. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. J Antimib Chemother 1986; 18: Suppl E: 193-202.Pestotnik S., Classen D.C., Evans R.S. et al. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother 1993; 27: 497-501.Pestotnik S., Classen D.C., Evans R.S. et al. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother 1993; 27: 497-501.Day I.P., Goudie J., Nishiki K. et al. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin, and meropenem. Toxicol Lett 1995; 76: 239-243.Day I.P., Goudie J., Nishiki K. et al. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin, and meropenem. Toxicol Lett 1995; 76: 239-243.Norrby S.R. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15: 87-90.Norrby S.R. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15: 87-90.Basoli A., Zarba E.Z., Mazzocchi P. et al. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 1997; 29: 503-508.Basoli A., Zarba E.Z., Mazzocchi P. et al. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 1997; 29: 503-508.Geroulanos S. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Antimicrob Chemotherapy 1995; 36 Suppl A: 195-205.Geroulanos S. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Antimicrob Chemotherapy 1995; 36 Suppl A: 195-205.Koppel B., Hauser W.A., Politis C. et al. Seizures in the critically ill: the role of imipenem. Epilepsia 2004; 42: 1590-1593.Koppel B., Hauser W.A., Politis C. et al. Seizures in the critically ill: the role of imipenem. Epilepsia 2004; 42: 1590-1593.Shah P., Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemotherapy 2003; 52: 538-542.Shah P., Isaacs R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemotherapy 2003; 52: 538-542.Paterson D., Ko W.-C., Von Gottberg A. et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26-32.Paterson D., Ko W.-C., Von Gottberg A. et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26-32.Vardakas K.Z., Tansarli G.S., Rafailidis P.I., Falagas M.E. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. JAC 2012; 67: 2793-2803.Vardakas K.Z., Tansarli G.S., Rafailidis P.I., Falagas M.E. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. JAC 2012; 67: 2793-2803.Ibrahim E., Sherman G., Ward S. et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-155.Ibrahim E., Sherman G., Ward S. et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-155.West M., Boulanger B.R., Fogarty C. et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 2592: 485-506.West M., Boulanger B.R., Fogarty C. et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 2592: 485-506.Cherif H., Bjorkholm M., Engervall P. et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004; 36: 593-600.Cherif H., Bjorkholm M., Engervall P. et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004; 36: 593-600.Erasmo A.A., Crisostomo A.C., Yan L.N. et al. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patiens with intra-abdominal infection. Asian J Surg 2004; 27: 227-235.Erasmo A.A., Crisostomo A.C., Yan L.N. et al. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patiens with intra-abdominal infection. Asian J Surg 2004; 27: 227-235.Kollef M.H. et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Critical Care 2012, 16: R218.Kollef M.H. et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Critical Care 2012, 16: R218.Kollef M.H., Sherman G., Ward S. et al. Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.Kollef M.H., Sherman G., Ward S. et al. Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.Valles J., Rello J., Ochagavia A. et al. Community-acquired bloodstream infection in critically ill adult patients. Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-1624.Valles J., Rello J., Ochagavia A. et al. Community-acquired bloodstream infection in critically ill adult patients. Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-1624.Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A. et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the Intensive Care Unit with sepsis. Crit Care Med 2003; 31: 2742-2751.Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A. et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the Intensive Care Unit with sepsis. Crit Care Med 2003; 31: 2742-2751.
The authors declare that there are no conflicts of interest present.